ATC/DDD Classification (Temporary)

ATC/DDD Classification (Temporary)

The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in March 2019.

Comments or objections to the decisions from the meeting should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology before 1 September 2019. If no

objections are received before this date, the new ATC codes and DDDs will be considered final and included in the January 2020 version of the ATC/DDD Index.

New ATC 5th level codes:

ATC level name/INN ATC code

vonoprazan A02BC08

homatropine methylbromide A03BB06

bempedoic acid C10AX15

rosuvastatin and fenofibrate C10BA09

rosuvastatin and ramipril C10BX17

Centella asiatica herba D03AX14

rifamycin D06AX15

econazole, combinations G01AF55

osilodrostat H02CA02

sarecycline J01AA14

omadacycline J01AA15

imipenem, cilastatin and beta-lactamase inhibitor J01DH56

lefamulin J01XX12

darunavir and ritonavir J05AR26

lamivudine, tenofovir disoproxil and dolutegravir J05AR27

ebola virus, live attenuated J07BX02

entrectinib L01XE56

fedratinib L01XE57

alpelisib L01XX65

selinexor L01XX66

tagraxofusp L01XX67

ATC level name/INN ATC code

upadacitinib L04AA44

darvadstrocel L04AX08

fremanezumab N02CD03¹⁾

remimazolam N05CD14

indacaterol and mometasone R03AK14

formoterol and tiotropium bromide R03AL10

formoterol, glycopyrronium bromide and budesonide R03AL11 indacaterol, glycopyrroinium bromide and mometasone R03AL12

revefenacin R03BB08

voretigene neparvovec S01XA27

folic acid V04CX02

methacholine V04CX03

mannitol V04CX04

13C-urea V04CX05

hexaminolevulinate V04CX06

edrophonium V04CX07

carbon monoxide V04CX08

patent blue V04CX09

1) New ATC 4th level, N02CD Calcitonin gene-related peptide (CGRP) antagonists

New ATC level codes (other than 5^th levels):

ATC level name New ATC code

Calcitonin gene-related peptide (CGRP) antagonists N02CD

Change of ATC level codes:

ATC-level names Previous ATC-code New ATC code

miltefosine L01XX09 P01CX04

erenumab N02CX07 N02CD01

galcanezumab N02CX08 N02CD02

Change of ATC level names:

ATC-code Previous ATC-level name New ATC-level name

A03CB04 methylhomatropine and

psycholeptics homatropine methylbromide and psycholeptics

B06AB Other hem products Heme products

B06AB01 hematin hemin

New DDDs:

ATC level name/INN DDD unit Adm.R ATC code

prasterone 6.5 mg V G03XX01

sarecycline 0.1 g O J01AA14

omadacycline 0.3

0.1 g

g O

P J01AA15

doravirine 0.1 g O J05AG06

baloxavir marboxil 40 mg O J05AX25

lesinurad 0.2 g O M04AB05

galcanezumab¹⁾ 4 mg P N02CD02

fremanezumab²⁾ 7.5 mg P N02CD03

fexinidazole 1.44 g O P01CA03

1) ATC code altered from N02CX08. New ATC 4th level N02CD valid from January 2020.

2) New ATC 4th level N02CD valid from January 2020.

WHO Collaborating Centre for Drug Statistics Methodology Oslo, May 2019

ATC/DDD Classification (Final)

The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in October 2018.

These are considered as final and will be included in the January 2020 version of the ATC/DDD Index.

New ATC 5th level codes:

ATC level name/INN ATC code

rabeprazole, amoxicillin and clarithromycin A02BD12 rabeprazole, amoxicillin and metronidazole A02BD13 vonoprazan, amoxicillin and clarithromycin A02BD14 vonoprazan, amoxicillin and metronidazole A02BD15

mosapride A03FA09

rifamycin A07AA13

sotagliflozin A10BK06

pegvaliase A16AB19

betrixaban B01AF04

ulinastatin B02AB05

ferrous sodium citrate B03AA12

luspatercept B03XA06

crizanlizumab¹⁾ B06AX01

amlodipine and celecoxib C08CA51

perindopril, bisoprolol and amlodipine C09BX04

fimasartan and amlodipine C09DB09

irbesartan, amlodipine and hydrochlorothiazide C09DX07

rosuvastatin and omega-3 fatty acids C10BA07

atorvastatin and omega-3 fatty acids C10BA08

rosuvastatin and fimasartan C10BX16

glycopyrronium D11AA01

tamsulosin and tadalafil G04CA54

Elagolix H01CC03

plazomicin J01GB14

enviomycin J04AB06

ATC level name/INN ATC code

Laninamivir J05AH04

elbasvir J05AP10

Grazoprevir J05AP11

daclatasvir, asunaprevir and beclabuvir J05AP58

lamivudine and dolutegravir J05AR25

tecovirimat J05AX24

baloxavir marboxil J05AX25

amenamevir J05AX26

favipiravir J05AX27

cemiplimab L01XC33

acalabrutinib L01XE51

quizartinib L01XE52

larotrectinib L01XE53

gilteritinib L01XE54

ivosidenib L01XX62

glasdegib L01XX63

entinostat L01XX64

darolutamide L02BB06

imlifidase L04AA41

siponimod L04AA42

ravulizumab L04AA43

opinercept L04AB07

risankizumab L04AC18

esketamine N06AX27²⁾

solriamfetol N06BA14

inotersen N07XX15

tafenoquine P01BA07

moxidectin P02CX03

vancomycin S01AA28

latanoprostene bunod S01EE06

latanoprost and netarsudil S01EE51

brolucizumab S01LA06

arginine and lysine V03AF11

New ATC level codes (other than 5^th levels):

Other hematological agents B06AX

Change of ATC level names:

Previous New ATC code

lactobacillus fermentum lactobacillus G01AX14 microspheres of human

albumin

perflutren, human albumin microspheres

V08DA01 microspheres of phospholipids perflutren, phospholipid

microspheres V08DA04

sulfur hexafluoride sulfur hexafluoride,

phospholipid microspheres V08DA05 perflubutane polymer

microspheres perflubutane, phospholipid

microspheres V08DA06

New DDDs:

ATC level name/INN DDD unit Adm.R ATC code

nabilone 3 mg O A04AD11

semaglutide 0.11 mg P A10BJ06

cerliponase alfa 21 mg P A16AB17

glycerol phenylbutyrate 15 g O A16AX09

pentosan polysulfate sodium 0.3 g O G04BX15

cefpodoxime and beta-lactamase inhibitor 0.4 g¹⁾ O J01DD64

levofloxacin 0.24 g Inhal.solution J01MA12

calcium aminosalicylate 15 g O J04AA03

enviomycin 1 g P J04AB06

vidarabine 0.7 g P J05AB03

peramivir 0.6 g P J05AH03

laninamivir 40 mg Inhal.powder J05AH04

asunaprevir 0.2 g O J05AP06

elbasvir 50 mg O J05AP10

grazoprevir 0.1 g O J05AP11

amenamevir 0.4 g O J05AX26

favipiravir 1.6 g O J05AX27

apalutamide 0.24 g O L02BB05

ATC level name/INN DDD unit Adm.R ATC code

Opinercept 7 mg P L04AB07

brodalumab 15 mg P L04AC12

pridinol 6 mg O M03BX03

erenumab 2.5 mg P N02CD01²⁾

sodium zirconium cyclosilicate 7.5 g O V03AE10

1) Refers to cefpodoxime. Decided at the meeting in the WHO ATC/DDD Working Group in March 2018.

2) ATC code altered from N02CX07. New ATC 4th level N02CD Calcitonin gene-related peptide (CGRP) antagonists valid from January 2020.

Changes of DDDs:

ATC level name/INN Previous DDD New DDD ATC code

liraglutide 1.2 mg P 1.5 mg P A10BJ02

WHO Collaborating Centre for Drug Statistics Methodology Oslo, May 2019

***